Venn Life Sciences Holdings PLC EUR1.2m Contract with Global Pharmaceutical Comp (8146U)
October 21 2014 - 2:00AM
UK Regulatory
TIDMVENN
RNS Number : 8146U
Venn Life Sciences Holdings PLC
21 October 2014
Venn Life Sciences Holdings Plc
("Venn" or the "Company" or the "Group")
EUR1.2m Contract with Global Pharmaceutical Company
Venn Life Sciences (AIM: VENN), a growing Clinical Research
Organisation (CRO) providing clinical trial management and
resourcing solutions to pharmaceutical, biotechnology and medical
device clients, announces the signing of a EUR1.2m agreement to
conduct a Phase IV clinical trial with a Global Pharmaceutical
Company specialising in allergic diseases.
The contract signing comes on the back of Venn completing the
acquisition of Cardinal Systems in France, a CRO specialising in
Data Management and Randomisation which enables Venn to offer the
full service portfolio with in-house services. The addition of
these services has been an instrumental factor in securing this
contract. With over 25 years in the business, Venn has extensive
experience in the management of paediatric trials. The study will
be run in over 70 sites across Europe with the objective of
recruiting 300 patients.
This now brings the total amount of new business won since May
to EUR6.6m and demonstrates as a larger Group, Venn is able to win
larger value pan-European multi-site contracts.
Speaking about the agreement, Venn CEO, Tony Richardson stated:
"With the recent addition to our service portfolio and our
geographic expansion throughout Europe, our clients are securely
making the decision to choose us as their clinical trial partner
for the future. I am particularly pleased that our first joint
contract win with Cardinal is so significant and so soon after
acquisition. I believe this represents an early endorsement of our
decision to acquire data management and IRS capabilities and we are
greatly encouraged by the pipeline for our new full service
offering."
Venn Life Sciences Holdings Plc
David Evans, Non-Executive Chairman Tel: +44(0)7980 541 893
Tony Richardson, Chief Executive Officer Tel: +353 154 99 341
Zeus Capital (Nominated Adviser and
Broker)
Ross Andrews/Andrew Jones (Corporate Tel: +44(0)161 831 1512
Finance)
Dominic Wilson (Institutional Sales) Tel: +44(0)20 7533 7721
Walbrook PR Ltd Tel: +44(0)20 7933 8787 or venn@walbrookpr.com
Paul McManus Mob: +44(0)7980 541 893
Lianne Cawthorne Mob: +44(0)7584 391 303
About Venn Life Sciences Limited: www.vennlifesciences.com
Venn Life Sciences is a Clinical Research Organisation providing
clinical trial management and resourcing solutions to
pharmaceutical, biotechnology and medical device organisations.
With dedicated operations in France, Germany, the Netherlands, the
UK and Ireland and Europe wide representation - Venn specialises in
rapid deployment and management of multisite projects. Venn
recently established an innovation division - InnoVenn - focused
primarily on breakthrough development opportunities in Skin
Science.
About Phase IV trials:
Phase IV trial is also known as post-marketing surveillance
Trial. Phase IV trials involve the safety surveillance
(pharmacovigilance) and ongoing technical support of a drug after
it receives permission to be sold. Phase IV studies may be required
by regulatory authorities or may be undertaken by the sponsoring
company for competitive or other reasons.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBLBDGUUDBGSG
Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024